In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARα protein and the PML retargeting on PML-nuclear bodies

Leukemia

Volumn 13, Issue 5, 1999, Pages 739-749

  Gianni M ^a,b   De The H ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

APL; Apoptosis; As2O3; CD437; NB4; PML RAR

Indexed keywords

ARSENIC; CASPASE 3; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RETINOIC ACID RECEPTOR; RETINOID; SERINE PROTEINASE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DEGRADATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL;

EID: 0344327127     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401419     Document Type: Article

References (75)

1. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Annu Oncol 1992; 5: 515-526.
2. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? (review). Cell 1995; 83: 859-869.
3. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade (overview). Cell 1995; 83: 835-839.
4. Lotan R. Effects of vitamin A and its analogs(retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980; 605: 33-91.
5. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-954.
6. Gudas L. Retinoids and vertebrae development. J Biol Chem 1994; 269: 15399-15402.
7. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev 1993; 14: 651-658.
8. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM, Evans RM. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA 1991; 88: 6092-6096.
9. Warrell R, de Thé H, Wang Z, Degos L. Acute promyelocytic leukemia. New Engl J Med 1993; 329: 177-189.
10. Grignani F, Ferrucci P, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci P. The acute promyelocytic leukemia specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431.
11. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM. A PML RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 2551-2556.
12. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARalpha under control of cathepsin G regulatory sequences. Blood 1997; 89: 376-387.
13. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP. Acute leukemia with promyelocytic features in PML/RAR alpha transgenic mice. Proc Natl Acad Sci USA 1997; 94: 5302-5307.
14. Daniel MT, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, Guillemin M-C, Degos L, Chomienne C, de Thé H. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82: 1858-1867.
15. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333-343.
16. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H. The t(15;17) translocation alters a nuclear body in a RA-reversible fashion. EMBO J 1994; 13: 1073-1083.
17. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A. Retinoic acid regulates aberrant nuclear localization of PML/RARα in acute promyelocytic leukemia cells. Cell 1994; 76: 345-356.
18. Warrell RPJ, Frankel SR, Miller WJJ, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreef M, Tafuri A, Jakubowski A, Gavrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1991; 324: 1385-1393.
19. Casini T, Grignani F, Pelicci PG. Genetics of APL and the molecular bases of retinoic acid treatment. Int J Cancer 1997; 70: 473-474.
20. Chomienne C, Fenaux P, Degos, L. Retinoid differentiation therapy in acute promyelocytic leukemia. FASEB J 1996; 10: 1025-1030.
21. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway. Cancer Res 1996; 56: 2945-2948.
22. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
23. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
24. Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y, Zhu J, Tang W, Sun G-L, Yang K-Q, Chen Y, Zhou L, Fang Z-W, Wang Y-T, Ma J, Zhang P, Zhang T-D, Chen S-J, Chen Z, Wang Z-Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
25. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978-3983.
26. Giannì M, Koken MHM, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310.
27. Rogaia D, Grignani F, Grignani F, Nicoletti I, Pelicci PG. The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells. Leukemia 1995; 9: 1467-1472.
28. Degos L. Differentiation therapy in acute promyelocytic leukemia: European experience. J Cell Physiol 1997; 173: 285-287.
29. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, Kastner PH, Berger R, Lanotte M. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological and molecular features. Leukemia 1992; 6: 1281-1287.
30. Bernard BA, Bernadon JM, Delescluse C, Martin B, Lenoir MC, Maignan J, Charpentier B, Pilgrim WR, Reichert U, Shroot B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem Biophys Res Commun 1992; 186: 977-983.
31. Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl) hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Int J Cancer 1997; 70: 484-487.
32. Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I, Nürnberg W, Stüting S, Stebut EV, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in Xenografts in vivo. J Cell Biol 1996; 135: 1889-1898.
33. Sun S-Y, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol 1997; 173: 279-284.
34. Hsu CA, Rishi AK, Su-Li X, Gerard TM, Dawson, MI, Schiffer C, Reichert U, Shroot B, Poirer GC, Fontana JA. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997; 89: 4470-4479.
35. Shao Z-M, Dawson MI, Li X-S, Rishi A-K, Shickh MS, Han Q-X, Ordonez JV, Shroot B, Fontana JA. p53 independent Go/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995; 11: 493-504.
36. Szondy Z, Reichert U, Bernardon J-M, Michel S, Tóth R, Ancian P, Ajzner E, Fesus L. Induction of apoptosis by retinoids and retinoic acid receptor γ-selective compounds in mouse thymocytes through a novel apoptosis paphway. Mol Pharmacol 1997; 51: 972-982.
37. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia. Blood 1991; 77: 1080-1086.
38. Giannì M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, Rambaldi A, Garattini E. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 1996; 87: 1520-1531.
39. Apfel C, Bauer F, Crettaz M, Forni L, Kamber M, Kaufmann F, LeMotte P, Pirson W, Klaus M. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci USA 1992; 89: 7129-7133.
40. Yoshimura H, Nagai M, Hibi S, Kikuchi K, Abe S, Hida T, Higashi S, Hishinuma I, Yamanaka T. A novel type of retinoic acid receptor antagonist: synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivates. j Med Chem 1995; 38: 3163-3173.
41. Ruchaud S, Duprez E, Gendron MC, Houge G, Genieser HG, Jastorff B, Doskeland SO, Lanotte M. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci USA 1994; 91: 8428-8432.
42. Wesselberg S, Janssen O, Rabelitz P. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T-cells. J Immunol 1993; 150: 4338-4345.
43. Gaub MP, Rochette-Egly C, Lutz Y, Ali S, Matthes H, Scheuer I, Chambon P. Immunodetection of multiple species of retinoic acid receptor alpha: evidence for phosphorylation. Exp Cell Res 1992; 201: 335-346.
44. Datta R, Kojiama H, Banach D, Bump NJ, Talanian RV, Alnemri ES, Weichselbaum RR, Wong WW, Kufe DW. Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem 1997; 272: 1965-1969.
45. Monczak Y, Trudel M, Lamph WW, Miller WHJ. Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997; 90: 3345-3355.
46. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996; 93: 2239-2244.
47. Dawson SP, Arnold JE, Mayer NJ, Reynolds SE, Billett MA, Gordon C, Colleaux L, Kloetzel PM, Tanaka K, Mayer RJ. Developmental changes of the 26S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death. J Biol Chem 1995; 270: 1850-1858.
48. Drexler HCA. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-860.
49. Boggs SE, McCormick TS, Lapetina EG. Glutathione levels determine apoptosis in macrophages. Biochem Biophys Res Commun 1998; 247: 229-233.
50. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996; 15: 6269-6279.
51. L fails to inhibit apoptosis mediated by a novel retinoid. Proc Am Ass Cancer Res 1998; 39: 274.
52. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Volgenstein B. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
53. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996; 271: 31723-31728.
54. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992; 356: 356-358.
55. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zend Z, Beibler DR, Poirer GG, Salvesen GS, Dixit VM. Yama/CPP32 B. A mammalian homolog of CED-3 is a CRM A-inhibitable protease that cleaves the death substrate poly(ADP-Ribose)polymerase. Cell 1995; 81: 801-809.
56. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MHM, Venturini L, Stadler M, Pavlovic J, Degos L, de Thé H. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995; 9: 2027-2033.
57. Duprez E, Lillehaug JR, Gaub MP, Lanotte M. Differential changes of retinoid-X receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells. Oncogene 1996; 12: 2443-2450.
58. Wright SC, Schellenberger U, Wang H, Wang Y, Kinder DH. Chemotherapeutic drug activation of the AP24 protease in apoptosis: requirement for caspase-3-like-proteases. Biochem Biophys Res Commun 1998; 245: 797-803.
59. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood 1998; 92: 2244-2251.
60. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen J-C, de Thé H. PML induces a novel caspase-independent death process. Nat Genet 1998; 20: 259-265.
61. Wang Z-G, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272.
62. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic fragmentation of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
63. Weil M, Jacobson MD, Coles HSR, Davies JJ, Gardner RL, Raff KD, Raff MC. Constitutive expression of the machinery for programmed cell death. J Cell Biol 1996; 133: 1053-1059.
64. Orth K, Chinnaiyan AM, Gang M, Froelich CJ, Dixit V. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996; 271: 16443-16446.
65. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 1997; 16: 2271-2281.
66. MacFarlane M, Cain K, Sun X-M, Alnemri ES, Cohen GM. Processing/activation of at least four interleukin-1 beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells. J Cell Biol 1997; 137: 469-479.
67. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
68. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
69. Kane DJ, Sarafian TA, Anton R, Hahan H, Gralla EB, Valentine JS, Ord T, Bredesen DE. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-1277.
70. Oridate N, Higuchi M, Hong WK, Lotan R. Pro-oxidant activity of N-(4-hydroxyphenyl) retinamide(4HPR) may mediate induction of apoptosis in carcinoma cells. Proc Amer Assoc Cancer Res 1996; 37: 232 (Abstr.).
71. Kroemer G, Martinez-AC. Pharmacological inhibition of programmed lymphocyte death. Immunol Today 1994; 15: 235-242.
72. Li Y, Lin B, Agadir A, Liu R, Dawson MI, Reed JC, Fontana JA, Bost F, Hobbs PD, Zheng Y, Chen G-O, Shroot B, Mercola D, Zhang X-K. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998; 18: 4719-4731.
73. Bullock G, Ray S, Reed J, Miyashita T, Ibrado AM, Huang Y, Bhalla K. Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells. Clin Cancer Res 1995; 1: 559-564.
74. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 1992; 267: 18278-18283.
75. Estus S, Zaks WJ, Freeman RS, Gruda M, Bravo R, Johnson EM. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 1994; 127: 1717-1728.